Early Weight Loss Linked to Lower Gastroesophageal Junction Carcinoma Survival Rates
source: pixabay.com

Early Weight Loss Linked to Lower Gastroesophageal Junction Carcinoma Survival Rates

Unintended weight loss is a symptom associated with many different forms of cancer. But what can this weight loss tell researchers about the patients and their outcomes? Healio shares a…

Continue Reading Early Weight Loss Linked to Lower Gastroesophageal Junction Carcinoma Survival Rates

Study of the Week: Early GI Cancer Screening is Recommended for Primary Immunodeficiency Patients

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Early GI Cancer Screening is Recommended for Primary Immunodeficiency Patients

 A Clinical Trial Confirms That Nivolumab Plus Chemotherapy Outperforms Immunotherapy Alone In Gastric Cancer Treatment

Healio recently published results of the CheckMate 649 study confirming the benefits of combining nivolumab and chemotherapy in treating newly diagnosed patients with gastroesophageal junction cancer and advanced gastric and…

Continue Reading  A Clinical Trial Confirms That Nivolumab Plus Chemotherapy Outperforms Immunotherapy Alone In Gastric Cancer Treatment
FDA Decision on Opdivo with Chemotherapy for Advanced Gastrointestinal Cancers will be Made Next Month
source: pixabay.com

FDA Decision on Opdivo with Chemotherapy for Advanced Gastrointestinal Cancers will be Made Next Month

By May 25th, 2021 the FDA will announce their decision regarding approval of Opdivo used in combination with chemotherapy for gastrointestinal cancers. Back in December, Priority Review was granted to…

Continue Reading FDA Decision on Opdivo with Chemotherapy for Advanced Gastrointestinal Cancers will be Made Next Month